Sidley represented Guardant Health, Inc (Nasdaq: GH) on its strategic partnership with Adicon to offer comprehensive genomic profiling tests to accelerate the development of new cancer therapies in China.
The collaboration will provide biopharmaceutical companies with access to Guardant Health’s broad range of cancer tests, which will help to advance their clinical trial and drug development programs.
As part of the collaboration, Guardant Health will license its industry-leading liquid biopsy technology to Adicon, including the Guardant360® and GuardantOMNI™ tests and the Guardant360 TissueNext™ tissue-based biopsy for patients with any solid cancerous tumor. These tests help researchers identify patients with cancers that have the appropriate molecular profile for their clinical programs, streamlining patient screening and clinical trial enrollment, and providing insights into patient response, tumor evolution, and resistance.
In addition, biopharmaceutical firms will have access to Guardant Reveal, which is the first blood-only test for detecting residual disease and monitoring cancer recurrence for early-stage cancer research and development.
Established in 2011, Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary tests, vast data sets, and advanced analytics. Headquartered in Hangzhou, China, Adicon is an independent third-party clinical laboratory company offering diagnostic testing outsourcing services to hospitals, clinics, and contract research organizations.
The Sidley team was led by senior counsel Chen Yang. Other team members included partner Ruchun Ji, managing associate Longbo Wang, and associate Diana Gong.
Sidley’s China Life Sciences practice is an integrated part of the firm’s Global Life Sciences practice, which has more than 200 dedicated lawyers globally. It is the only Band One firm ranked by Chambers Asia Pacific/Greater China Region for 13 consecutive years. It advises clients across the full spectrum of the business lifecycle, ranging from formation, corporate governance, and compliance operations for startups to collaboration, licensing, commercialization, and filing in the business development phase, including initial public offering, refinancing, and bonds/notes issuance, as well as domestic and cross-border mergers and acquisitions, asset restructuring, dispute resolution and international arbitration, equity incentive plans, and privatizations.
